Integration of Immunotherapy Across the Spectrum of Lung Cancer Karen Kelly, MD Professor of...

Integration of Immunotherapy Across the Spectrum of Lung Cancer

Karen Kelly, MDProfessor of Medicine

Associate Director for Clinical ResearchJennifer Rene Harmon Tegley and Elizabeth Erica Harmon

Endowed Chair in Cancer Clinical ResearchUC Davis Comprehensive Cancer Center

Objectives

1.Review the current status of immunotherapy

2. Identify determinants of response

3.Discuss strategies to enhance efficacy

Patient achieved a PR but 4 months later a surveillance scan revealed liver metastases. His sister is a nurse and they want to know about immunotherapy.

Case PresentationDW is a 54-year-old white male with a T2aN3M0, Stage III-B squamous carcinoma of the left lung diagnosed in December 2013. The patient received concurrent chemoradiation therapy with weekly pacltaxel and carboplatin followed by two cycles of full dose paclitaxel + carboplatin.

PMH: Type II DM, HTN, COPD, sleep apneaSH: Former smoker quit in 2008; 30 pack yearsPE: Mildly obese WM; PS 0

I informed the patient that an immune checkpoint inhibitor (ICI) was not FDA approved. I evaluated him for an ICI clinical trial but he was ineligible due to lack of tissue and he was too anxious to wait for a biopsy to be performed and analyzed.

What would you recommend?1.Gemcitabine and carboplatin2.Docetaxel3.Docetaxel and ramicirumab4.Gemcitabine5.RFA to the two liver lesions

Case Presentation

The patient was treated with docetaxel for 4 cycles and progressed in the liver with multiple new lesions. He underwent a liver biopsy and was placed on a phase I trial of an PDL-1 inhibitor. He is s/p 2 cycles with a MR

Case Presentation

Basic Immunology

The innate response is the rapidrecognition and eradication of invading pathogens (macrophages, monocytes, eosinophils, NK cells) and soluble mediators (activation of the complement cascade and acute phase reactants)

Activation of the innate response triggers the expression of costimulatory molecules and cytokines that allows for the specific adaptive response by cellular (T and B cells) andhumoral elements.

Activation requires antigenic fragments be presented by MHC to antigen specific receptors on cytotoxic (CD8) T cells

Ploegh HL Cancer Immunol Res 1:5-10; 2013; Ploegh HL Science 280 248-253, 1998

History of Immunotherapy in Lung Cancer

1970 1980 1990 2000 2010

CALGBLS-SCLC

Chemo XRT ± BCG

MAGRITStage 1B-III

Adj MAGE-A3 vs. Placebo

SWOG LS-SCLC

Maintenanceα Interferon

vs. OBS

LCSG 771Stage I NSCLC

Adj BCGvs. Placebo

STARTStage III NSCLCAdj Tecemotide

vs. Placebo

START2Stage III NSCLCAdj Tecemotide

vs. Placebo

SILVALS-SCLC

Maint Bec2/BGGvs. Observation

Randomized Phase III Trials

1970 1980 1990 2000 2010

Cancer Immunity Cycle

Chen DS, et al. Immunity. 39:1-10, 2013.

T Cell Targets For ImmunoregulatoryAntibody Therapy

Mellman I et al. Nature: 480: 480-9, 2011

Immune Checkpoint Inhibitors

T cell death

Sznol M et al Clin Can Res 19:1021-1034, 2013

†at clinically relevant doses

IgG1 wtCuretech Anti-PD-1

ADCC intact Potential to deplete activated T

cells and TILs and diminish activity

Blocks PD-1/PD-L2 interaction in lungs

Potential for autoimmune pneumonitis

IgG4 hinge mutantBMS Anti-PD-1Merck Anti-PD-1

40% reduced ADCC† Potential to deplete activated T

cells and TILs and diminish activity

Blocks PD-1/PD-L2 interaction in lungs

Potential for autoimmune pneumonitis

IgG1 EngineeredGenentech Anti-PD-L1

MedI-4736

No ADCC† Decreased potential to deplete

activated T cells and TILs

Leaves PD-1/PD-L2 interaction intact in lungs

Decreased potential for autoimmune pneumonitis

Blocks PD-L1/B7.1 interaction Potential for enhanced priming

Examples:

Courtesy of Dr. Herbst

Comparison of Therapeutic Antibodies Blocking PD-1/PDL-1 Interaction

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M.

Tumor Type (dose, mg/kg)

No. Pts OR (CR/PR)No. Pts (%)

SD 24 wkNo. Pts (%)

PFS (mos,median)

NSCLC(1-10)

129 22 (17) 13 (10) 2.3

MEL(0.1-10)

107 33 (31) 7 (7) 3.7

RCC(1 or 10)

34 10 (29) 9 (27) 7.3

Anti-tumor activity consistent across the drug class

Immune Checkpoint Inhibitors

Agent NRR

N (%)

NSCLC

Nivolumab1 129 22 (17)

MK-34752,3 33129

7 (21)25 (19)

MPDL3280A4 53 12 (23)

BMS 9365595 49 5 (10)

MEDI-47366 6 3/6 (50)

1Brahmer et. al. WCLC, 2013, 2Garon et. al. WCLC 2013, 3Ghandi et. al. AACR 2014, 4Horn et. al. WCLC 2013, 5Brahmer et. al. NEJM 2012, 6 Khleif et. al. WCLC 2013

Characteristics of Responses in NSCLC Patients Treated With Nivolumab

Time to and duration of response while on treatment

Time to response

Ongoing response

Response duration followinglatest reported dose of therapy

Time (week)

0 16 32 48 64 80 96 112 128 144 160

Squamous

Non-squamous

• Response occur within 8-12 weeks (black dot)

• Responses occur in nonsquamous and squamous histology

• Responses can last after agent has been discontinued (red bar)

Brahmer J et al. J Thorac Oncol 2013; 8(2s), abstr MO18.03, S365

OS by Nivolumab Dose in NSCLC Patients

Censored

0 6 12 18 24 3027211593 33 36 42 48 5439 45 51 57

2-year OS Rate 45% (9 patients at risk)

1-year OS Rate 56% (17 patients at risk)

0

10

20

30

40

50

60

70

80

90

100

OS

(%

)

Months Since Treatment Initiation

Group Median OS, mo (95% CI)

1 mg/kg 9.2 (5.3, 11.1)

3 mg/kg 14.9 (7.3, –)

10 mg/kg 9.2 (5.2, 12.4)

ORR was 3%, 24.3% and 20.3%, respectively for nivolumab 1, 3, and 10 mg/kg doses, respectively

Rizvi et al. LALC Meeting 2014

Mechanism of Action

CD8+ T cells Activation of cytotoxic T cells Increased γ interferonHerbst RS et al. Nature 515: 563-7, 2014

Phase II Trial: Immune Checkpoint Inhibitor

Ramalingam S et al. CMSTO, 2014

Phase II Trial: Immune Checkpoint Inhibitor

Ramalingam S et al. CMSTO, 2014

*Based on July 2014 DBL; Symbols represent censored observations

CheckMate -017, A Phase 3 Study of Opdivo (Nivolumab) Compared to Docetaxel in Patients with Second-Line Squamous Cell Non-small Cell Lung Cancer (BMS press release, January 2015)

Docetaxel75 mg/m2 q 3 wks

Previously Tx

Squamous Cell Histology

N=272

Nivolumab3 mg/kg q 3 wks

RANDOMIZATION

Nivolumab Docetaxel

Nivolumab

ALK Gene FusionROSI Gene Fusion

Squamous Cell

Crizotinib

Wild typeEGFR

Mutation +

Platinum with Pemetrexed Or

Platinum with Taxane

+ Bevacizumab*

Platinum Doublet***

ALK+

ErlotinibAfatinib

+ Bevacizumab

Treatment as per wild type

algorithmNivolumab

ErlotinibPemetrexed

First linetreatment

Maintenance(responders only)

Non-Squamous Cell

Second/Third Line treatment

Docetaxel**Pemetrexed** Erlotinib**

*Bevacizumab is not recommended in patients with untreated brain metastases, clinically significant hemoptysis or tumor cavitation **Treatment agent based on prior treatments, side effects profile, patient preference***Common platinum partners include Paclitaxel, Docetaxel, Abraxane, Gemcitabine, Vinorelbine

Docetaxel + Ramucirumab

Standard of Care Treatment Algorithm for Patients with Advanced NSCLC with PS 0-2

Erlotinib

Second line Phase III Trials

Trial Agent PD-L1 Status

Checkmate 057

Nivolumab vs. docetaxel (non-squamous)

Not required

Keynote 010 Pembrolizumab vs. docetaxel PD-L1 positive

OAK MPDL3280A vs. docetaxel PD L1 positive

LUNG-MAP MEDI4736 vs docetaxel Not required

KEYNOTE-001: Randomized Dose Comparison

Objectives

• Evaluate safety, tolerability, and clinical activity of pembrolizumab

• Evaluate correlation between clinical activity of pembrolizumab and PD-L1 expression

Mandatory Biopsy Within 60 Days of First Dose

Pembro 10 mg/kg Q3W

Pembro 10 mg/kg Q2W

Progressive Disease

Progressive Disease

R*1:1

• Treatment-naïve, stage IV NSCLC• ECOG PS 0-1• EGFR negative• No ALK rearrangement• PD-L1 positive (≥1% staining)• No systemic steroid• No autoimmune disease• No or stable brain mets

Balmanoukian SA, et al. Abstract #2

*First 11 patients were randomized to 2 mg/kg or 10 mg/kg Q3W

First Line Immunotherapy in Advanced NSCLC

Antitumor Activity by Pembrolizumab Dose

Pembro Dose

RECIST v1.1, Central Review irRC, Investigator Review

n

ORR DCR

n

ORR DCR

n (%)[95% CI]

n (%)[95% CI]

n (%)[95% CI]

n (%)[95% CI]

2 mg/kg Q3W

62 (33%) [4%-78%]

3 (50%) [12%-88%]

64 (67%)

[22%-96%]5 (83%)

[36%-100%]

10 mg/kg Q3W

204 (20%)

[6%-44%]14 (70%)

[46%-88%]22

10 (46%) [24%-68%]

18 (82%) [60%-95%]

10 mg/kg Q2W

165 (31%)

[11%-59%]10 (63%)

[35%-85%]17

7 (41%) [18%-67%]

12 (71%) [44%-90%]

Total 4211 (26%)

[14%-42%]27 (64%) [48%–78%]

4521 (47%)

[32%-62%]35 (78%)

[63%-89%]

Interim Median PFS: • 27.0 weeks (95% CI, 13.6-45.0) by RECIST v1.1 per central review • 37.0 weeks (95% CI, 27.0-NR) by irRC per investigator review

Maximum Percent Change from Baseline in Tumor Size in Evaluable Patients (N=35)

10 mg/kg Q3W

10 mg/kg Q2W

2 mg/kg Q3W

* Still on treatment

*

* * * * * * * * * * * * * * *

* * ** *

(Central Review, RECIST v1.1)

Rizvi NA et al. J Clin Oncol. 32(5s) Abstract 8007, 2014

Time to and Durability of Response

• 11 of 11 (100%) responses are ongoing– Median duration of response not reached

(median follow-up, 36 weeks)• 7 of 11 (64%) responders remain on treatment

– Median duration of treatment: 27.1 weeks (range, 15.0+ – 48.3+)

• 19 of 21 (90%) responses are ongoing– Median duration of response not reached

(median follow-up, 36 weeks)• 18 of 21 (86%) responders remain on treatment– Median duration of treatment: 27.1 weeks (range, 6.1 – 57.1+)

RECIST v1.1 Central Review

0 10 20 30 40 50Time, weeks

Ind

ivid

ual

Pat

ien

ts T

reat

ed W

ith

Pem

bro

irRC Investigator Review

0 10 20 30 40 50 60Time, weeks

Ind

ivid

ual

Pat

ien

ts T

reat

ed W

ith

Pem

bro

Pembro 2 mg/kg Q3WPembro 10 mg/kg Q3WPembro 10 mg/kg Q2W

Partial ResponseProgressionOn Treatment

Rizvi NA et al. J Clin Oncol. 32(5s) Abstract 8007, 2014

First Line Immunotherapy in Advanced NSCLC

Pembrolizumab Nivolumab

Number of Patients 45 20

ORR 26% 30%

SD 38% 35%

PFS (median) 27 weeks 36 weeks

Gettinger SN et al. ASCO 2014 #8024

CA209-012 (CheckMate 012) Study Design:

Nivolumab 10 mg/kg IV Q3W until disease progression or unacceptable toxicity

Primary objective: safety and tolerabilitySecondary objectives: ORR and PFS rate at 24 weeks

Exploratory objective: OS

Squamous Non-squamous Any histology

Nivolumab 5 mg/kg IV Q3W until disease progression or

unacceptable toxicity

Nivolumab 10 mg/kg IV Q3W + Gem 1250 mg/m2

+ Cis 75 mg/m2

(four 21-day cycles)

Nivolumab 10 mg/kg IV Q3W + Pem 500 mg/m2 + Cis 75 mg/m2

(four 21-day cycles)

Nivolumab 10 mg/kg IV Q3W + Pac 200 mg/m2

+ Carb AUC 6(four 21-day cycles)

Nivolumab 5 mg/kg IV Q3W + Pac 200 mg/m2

+ Carb AUC 6(four 21-day cycles)

Chemotherapy-naïve patients with stage IIIB or IV NSCLC

Antonia SJ et al. CMSTO Abstract #3, 2014

First Line Immunotherapy + Chemotherapy in Advanced NSCLC

Efficacy Endpoints

Nivolumab 10 mg/kg Nivolumab 5 mg/kg

Gem/Cis (n = 12)

Pem/Cis (n = 15)

Pac/Carb (n = 15)

Pac/Carb(n = 14)

ORR, % 33 47 47 43

SD, % 58 47 27 43

18-month OS rate, % 33 60 40 86

Median OS, weeks 51 83 65 NR

NR = not reached

Overall Survival by Treatment Arm

Time Since First Dose (Weeks)

OS

(%

)

0

20

40

60

80

100

B/L 12 24 36 48 60 72 84 96 108 120 132

Regimen mOS (wks)

Nivolumab 10 mg/kg + Gem/Cis 51

Nivolumab 10 mg/kg + Pem/Cis 83

Nivolumab 10 mg/kg + Pac/Carb 65

Nivolumab 5 mg/kg + Pac/Carb NR

x

Ongoing Phase III Trials

Trial Line of Therapy

Agent PD-L1 Status

CheckMate 026 First Nivolumab vs. investigator choice

chemotherapy

PD-L1 positive

Keynote 042/42 First Pembrolizumab vs. investigator choice

chemotherapy

PD-L1 positive

ARCTIC Third Line MEDI4736 vs. Chemotherapy

Not required

PACIFIC Locally Advanced

Following concurrent chemo-RT vs. placebo

Not required

Phase III Trials in Development: 1) Maintenance therapy in advanced NSCLC2) Adjuvant therapy

Pseudo-Progression

iRECIST

May occur in 7-10% of patients

Comparison: RECIST-irRC Criteria*

Complete Response (CR)

Disappearance of all extranodal target lesions. All pathological lymph nodes must have decreased to <10 mm in short axis

Disappearance of all lesions in two consecutive observations not less than 4 weeks apart

Partial Response (PR) At least a 30% decrease in the SLD of target lesions, taking as reference the baseline sum diameters

≥50% decrease in tumor burden compared with baseline in two observations at least 4 weeks apart

Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD

50% decrease in tumor burden compared with baseline cannot be established nor 25% increase compared with nadir

Progressive Disease (PD)

SLD increased by at least 20% from the smallest value on study (including baseline, if that is the smallest)The SLD must also demonstrate an absolute increase of at least 5 mm (two lesions increasing from 2 mm to 3mm, for example, does not qualify)

At least 25% increase in tumor burden compared with nadir (at any single time point) in two consecutive observations at least 4 weeks apart

*Total Burden=SPD index lesions + SPD new, measurable lesions

RECIST irRCNew, measurable lesions (i.e. ≥5 x 5 mm)

Always represent PD Incorporated into tumor burden

New, nonmeasurable lesions (i.e. <5 x 5 mm)

Always represent PD Do not define progression (but preclude irCR)

Non-index lesions Changes contribute to defining BOR of CR, PR, SD, and PD

Contribute to defining irCR (complete disappearance required)

Wolchok J et al Clin Can Res 19:7412-7420, 2009

Treatment Related Adverse Events

System Immune Related Adverse Events

Gastrointestinal Colitis (Diarrhea, perforation)

Renal Acute Interstitial Nephritis (Increased serum Creatinine)

Pulmonary Pneumonitis (dyspnea, cough)

Dermatologic Dermatitis (Lichenoid/ spongiotic dermatitis, rash), Vitaligo

Hepatic Hepatitis (elevated LFTs)

Neurologic Central and Peripheral (Aseptic Meningitis, Guillan-Barre Syndrome, Myasthenia Gravis

Endocrine Hypophysitis, thyroiditis, adrenal insufficiency

Ocular Uveitis, Iritis

• Fatigue is the most common AE (24%)• Grade 3-4 AEs are uncommon (6-12.6%)

Identifying Predictor(s) of Response

Responses are higher in PD-L1+ tumors but seen in PD-L1- tumors

Nivolumab (anti-PD-1)

Pembrolizumab (anti-PD-1)

MEDI4736 (anti-PD-L1)

MPDL3280A (anti-PD-L1)

Solid

tumors Mel Mel Mel

NSCLC

NSCLC RCC

H/N Mel

NSCLC

NSCLC

NSCLC

NSCLC

Bladder Mel

NSCLC

Solid

tumors

0

10

20

30

40

50

60

70

80

all patientsPD-L1+PD-L1-

Lipson, Taube, et al. Semin Oncol. In press.


PD-L1 IHC Expression By Various Assays

Tumor GNE DAKO 28-8 Merck CC23 5H1

Melanoma 40% 45% 71% 42%

NSCLC 45-50% 49% 45% (25% if ≥50% Staining)

Renal 20% 24%

Bladder 21% 28%

Head And Neck 31% 46%

Glioblastoma 25% 100%

• No validated assay• Variable cut off levels for positivity

Challenges

PD-L1 positive (TC)PD-L1 positive (IC)PD-L1 negative

Identifying Predictor(s) of Response Immune Cell PD-L1 Expression

Patients treated with MDPL3280A

NSCLC

Herbst RS et al. Nature 515: 563-7, 2014


Prevalence of PD-L1 IHC Expression?Prognostic significance of PD-L1 Expression?

Author N Stage (TC)PD-L1 (IC)PD-L1 Prognosis

D’Incecco2015 122 IV 55.3%

Herbst2015 184 IV 24% 26%

Velcheti2014

204 340

I-IVI-IV

25%36%

PD-L1 associated with better survival

Mu2011 109 I-IV 53% PD-L1 associated

with poor survival

Kowanetz 2010

254 (adeno) 37 (adeno) 139 (squamous) 16 (squamous)

I-IIIa IIIb-IV

I-IIIa IIIb-IV

31%19%31%31%

49%27%54%38%

D’Incecco A et al. Br J Can 112: 95-102, 2015; Herbst RS et al. Nature 515: 563-7, 2014Velcheti V et al. Lab Invest 94: 107-16, 2014; Mu CY et al. Med Oncol 28: 682-8, 2011Kowanetz M et al. WCLC 2013 Abstract

Tumor-Infiltrating Lymphocytes (TIL cells)

The presence of TIL cells at diagnosis

correlates with improved clinical

outcomes

CD3/AE1AE3

Zhang L et al. NEJM 348:203-13, 2003Galon J et al. Science 313: 1960-4, 2006Azimi F et al. J Clin Oncol 30: 2678-83, 2012Adams S et al. J Clin Oncol 2014 [Epub ahead of print]

Ovarian

Colon

Melanoma

Breast


Tumor-Infiltrating Lymphocytes (TIL cells)


Schalper, KA et al. JNCI 107:epublished Feb 3, 2015

• 552 patients from two cohorts• TIL cells did not correlate with OS• CD8 expression is an independent favorable prognostic marker

Identifying Predictor(s) of Resistance

CD8 negative Minimal CD8 expression Tumor rim CD8 expression

No evidence of CD8 T cell activityHerbst RS et al. Nature 515: 563-7, 2014


Mutational Burden

Rizvi NA et al. Science 348:124-8, 2015

11/431/10

n=17n=17

n=16n=18

Median PFSNR vs 3.4 moHR 0.19 (0.08-0.47)P = 0.0004RR 59% vs 12%

Median PFSNR vs 3.5 moHR 0.15 (0.06-0.39)P = 0.0001ORR 56% vs 17%

Median PFS14.5 mo vs 3.5 moHR 0.23 (0.09-0.58)P = 0.0002

• Median values used to determine high vs low• No mutations or copy number alterations in CD274 (PDL-1 gene)• Smoking history did not discriminate for responders• Molecular smoking signature correlated with mutational burden

Combined Immunomodulation

Chen DS, et al. Immunity. 2013;39:1-10.

Phase I Trial of Ipilumumab and Nivolumab in First Line NSCLC N=49

Antonia SJ, et al. J Clin Oncol 32:5s, 2014 (suppl; abstr 8023)

ORRs: 8/49 (16%); PFS: 14 -16 wks

Treatment related Grade 3 or 4 AE (49%); Discontinuation (35%)

Combined Immunomodulation

Top Questions about Immune Checkpoint Inhibitors

• Anti- PD1 vs. Anti-PDL1?• Ideal schedule/duration of therapy?• Will/should PDL1 status guide treatment?• Sequencing/Maintenance Therapy? • Optimal Combinations?• Mechanisms of Resistance?

• Immune checkpoint inhibitors represent a new class of agents that are showing great promise for the treatment of advanced NSCLC.

• Immune checkpoint inhibitors have a distinct toxicity profile and response assessment that must be taken into account in treating patients with these agents.

• Immune checkpoint inhibitors represent the first of several strategies targeting the immune system for therapeutic benefit.

Summary

I have your molecular profile, tumor PDL-1, Immune PDL-1

and CD8 expression levels and a variety of other tumor assay

results for us to discussand use to select your

treatment

• Mrs. LW is a 45 year old Asian never smoker with stage IV adenocarcinoma of the lung with multiple bilateral pulmonary nodules and bone metastases. Her tumor was EGFR/ALK/ROS-1 wild type and PDL-1 negative. What is her chance of responding to an immune checkpoint inhibitor?

1. 70%

2. 50%

3. 10%

4. 5%

Question

• What immune related adverse event occurs in >5% of patients receiving nivolumab?

1. Colitis

2. Pneumonitis

3. Hepatitis

4. Hypthyroidism

5. Uveitis

Question

Integration of Immunotherapy Across the Spectrum of Lung Cancer Karen Kelly, MD Professor of...

Documents

Transcript of Integration of Immunotherapy Across the Spectrum of Lung Cancer Karen Kelly, MD Professor of...